These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 12951129)

  • 41. 6-Acylamino-2-amino-4-methylquinolines as potent melanin-concentrating hormone 1 receptor antagonists: structure-activity exploration of eastern and western parts.
    Ulven T; Little PB; Receveur JM; Frimurer TM; Rist O; Nørregaard PK; Högberg T
    Bioorg Med Chem Lett; 2006 Feb; 16(4):1070-5. PubMed ID: 16289819
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Dihydropyrrole[2,3-d]pyridine derivatives as novel corticotropin-releasing factor-1 antagonists: mapping of the receptor binding pocket by in silico docking studies.
    Di Fabio R; Arban R; Bernasconi G; Braggio S; Blaney FE; Capelli AM; Castiglioni E; Donati D; Fazzolari E; Ratti E; Feriani A; Contini S; Gentile G; Ghirlanda D; Sabbatini FM; Andreotti D; Spada S; Marchioro C; Worby A; St-Denis Y
    J Med Chem; 2008 Nov; 51(22):7273-86. PubMed ID: 18975927
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Anxiolytic-like effects of the corticotropin-releasing factor1 (CRF1) antagonist DMP904 [4-(3-pentylamino)-2,7-dimethyl-8-(2-methyl-4-methoxyphenyl)-pyrazolo-[1,5-a]-pyrimidine] administered acutely or chronically at doses occupying central CRF1 receptors in rats.
    Lelas S; Wong H; Li YW; Heman KL; Ward KA; Zeller KL; Sieracki KK; Polino JL; Godonis HE; Ren SX; Yan XX; Arneric SP; Robertson DW; Hartig PR; Grossman S; Trainor GL; Taub RA; Zaczek R; Gilligan PJ; McElroy JF
    J Pharmacol Exp Ther; 2004 Apr; 309(1):293-302. PubMed ID: 14742750
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Design, synthesis, and biological evaluation of 1,2,3,7-tetrahydro-6h-purin-6-one and 3,7-dihydro-1h-purine-2,6-dione derivatives as corticotropin-releasing factor(1) receptor antagonists.
    Hartz RA; Nanda KK; Ingalls CL; Ahuja VT; Molski TF; Zhang G; Wong H; Peng Y; Kelley M; Lodge NJ; Zaczek R; Gilligan PJ; Trainor GL
    J Med Chem; 2004 Sep; 47(19):4741-54. PubMed ID: 15341489
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Design and synthesis of tricyclic imidazo[4,5-b]pyridin-2-ones as corticotropin-releasing factor-1 antagonists.
    Guo Z; Tellew JE; Gross RS; Dyck B; Grey J; Haddach M; Kiankarimi M; Lanier M; Li BF; Luo Z; McCarthy JR; Moorjani M; Saunders J; Sullivan R; Zhang X; Zamani-Kord S; Grigoriadis DE; Crowe PD; Chen TK; Williams JP
    J Med Chem; 2005 Aug; 48(16):5104-7. PubMed ID: 16078829
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Receptor binding, behavioral, and electrophysiological profiles of nonpeptide corticotropin-releasing factor subtype 1 receptor antagonists CRA1000 and CRA1001.
    Okuyama S; Chaki S; Kawashima N; Suzuki Y; Ogawa S; Nakazato A; Kumagai T; Okubo T; Tomisawa K
    J Pharmacol Exp Ther; 1999 May; 289(2):926-35. PubMed ID: 10215672
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Synthesis, structure-activity relationships, and in vivo evaluation of N3-phenylpyrazinones as novel corticotropin-releasing factor-1 (CRF1) receptor antagonists.
    Hartz RA; Ahuja VT; Arvanitis AG; Rafalski M; Yue EW; Denhart DJ; Schmitz WD; Ditta JL; Deskus JA; Brenner AB; Hobbs FW; Payne J; Lelas S; Li YW; Molski TF; Mattson GK; Peng Y; Wong H; Grace JE; Lentz KA; Qian-Cutrone J; Zhuo X; Shu YZ; Lodge NJ; Zaczek R; Combs AP; Olson RE; Bronson JJ; Mattson RJ; Macor JE
    J Med Chem; 2009 Jul; 52(14):4173-91. PubMed ID: 19552437
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Monkey corticotropin-releasing factor1 receptor: Complementary DNA cloning and pharmacological characterization.
    Oshida Y; Ikeda Y; Chaki S; Okuyama S
    Life Sci; 2004 Feb; 74(15):1911-24. PubMed ID: 14761672
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Arylamidrazones as novel corticotropin releasing factor receptor antagonists.
    Wilson DM; Termin AP; Mao L; Ramirez-Weinhouse MM; Molteni V; Grootenhuis PD; Miller K; Keim S; Wise G
    J Med Chem; 2002 May; 45(11):2123-6. PubMed ID: 12014949
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Substituted tetraazaacenaphthylenes as potent CRF1 receptor antagonists for the treatment of depression and anxiety.
    St-Denis Y; Di Fabio R; Bernasconi G; Castiglioni E; Contini S; Donati D; Fazzolari E; Gentile G; Ghirlanda D; Marchionni C; Messina F; Micheli F; Pavone F; Pasquarello A; Sabbatini FM; Zampori MG; Arban R; Vitulli G
    Bioorg Med Chem Lett; 2005 Aug; 15(16):3713-6. PubMed ID: 15946843
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Potent and long-acting corticotropin releasing factor (CRF) receptor 2 selective peptide competitive antagonists.
    Rivier J; Gulyas J; Kirby D; Low W; Perrin MH; Kunitake K; DiGruccio M; Vaughan J; Reubi JC; Waser B; Koerber SC; Martinez V; Wang L; Taché Y; Vale W
    J Med Chem; 2002 Oct; 45(21):4737-47. PubMed ID: 12361401
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Characterisation using microphysiometry of CRF receptor pharmacology.
    Smart D; Coppell A; Rossant C; Hall M; McKnight AT
    Eur J Pharmacol; 1999 Aug; 379(2-3):229-35. PubMed ID: 10497910
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Quantitative pharmacological analysis of antagonist binding kinetics at CRF1 receptors in vitro and in vivo.
    Ramsey SJ; Attkins NJ; Fish R; van der Graaf PH
    Br J Pharmacol; 2011 Oct; 164(3):992-1007. PubMed ID: 21449919
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Pyrrolo[1,2-b]pyridazines, pyrrolo[2,1-f]triazin-4(3H)-ones, and related compounds as novel corticotropin-releasing factor 1 (CRF₁) receptor antagonists.
    Saito T; Obitsu T; Kohno H; Sugimoto I; Matsushita T; Nishiyama T; Hirota T; Takeda H; Matsumura N; Ueno S; Kishi A; Kagamiishi Y; Nakai H; Takaoka Y
    Bioorg Med Chem; 2012 Jan; 20(2):1122-38. PubMed ID: 22196514
    [TBL] [Abstract][Full Text] [Related]  

  • 55. 3D-QSAR study of corticotropin-releasing factor 1 antagonists and pharmacophore-based drug design.
    Ye Y; Liao Q; Wei J; Gao Q
    Neurochem Int; 2010 Jan; 56(1):107-17. PubMed ID: 19782115
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Synthesis and structure-activity relationships of 8-substituted-2-aryl-5-alkylaminoquinolines: Potent, orally active corticotropin-releasing factor-1 receptor antagonists.
    Takeda K; Terauchi T; Hashizume M; Shikata K; Taguchi R; Murata-Tai K; Fujisawa M; Takahashi Y; Shin K; Ino M; Shibata H; Yonaga M
    Bioorg Med Chem; 2012 Nov; 20(22):6559-78. PubMed ID: 23062820
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Synthesis of 1-methyl-3-phenylpyrazolo[4,3-b]pyridines via a methylation of 4-phthalimino-3-phenylpyrazoles and optimization toward highly potent corticotropin-releasing factor type-1 antagonists.
    Huang CQ; Wilcoxen K; McCarthy JR; Haddach M; Grigoriadis D; Chen C
    Bioorg Med Chem Lett; 2003 Oct; 13(19):3371-4. PubMed ID: 12951128
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Synthesis, structure-activity relationships, and anxiolytic activity of 7-aryl-6,7-dihydroimidazoimidazole corticotropin-releasing factor 1 receptor antagonists.
    Han X; Michne JA; Pin SS; Burris KD; Balanda LA; Fung LK; Fiedler T; Browman KE; Taber MT; Zhang J; Dubowchik GM
    Bioorg Med Chem Lett; 2005 Sep; 15(17):3870-3. PubMed ID: 15990298
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Optimising metabolic stability in lipophilic chemical space: the identification of a metabolically stable pyrazolopyrimidine CRF-1 receptor antagonist.
    Miller DC; Klute W; Calabrese A; Brown AD
    Bioorg Med Chem Lett; 2009 Nov; 19(21):6144-7. PubMed ID: 19782566
    [TBL] [Abstract][Full Text] [Related]  

  • 60. In vitro intrinsic clearance-based optimization of N3-phenylpyrazinones as corticotropin-releasing factor-1 (CRF1) receptor antagonists.
    Hartz RA; Ahuja VT; Rafalski M; Schmitz WD; Brenner AB; Denhart DJ; Ditta JL; Deskus JA; Yue EW; Arvanitis AG; Lelas S; Li YW; Molski TF; Wong H; Grace JE; Lentz KA; Li J; Lodge NJ; Zaczek R; Combs AP; Olson RE; Mattson RJ; Bronson JJ; Macor JE
    J Med Chem; 2009 Jul; 52(14):4161-72. PubMed ID: 19552436
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.